PDCD1 and colitis: Although starting patients like ours on sirolimus when they are already on immunosuppressive medications including immunotherapy (pembrolizumab) has the risk of further compromising their immune system, studies show that sirolimus improves programmed cell death 1 blockade efficacy and improves the immune-related gastrointestinal adverse effects such as colitis, which our patient had [16,17].